USA flag logo/image

An Official Website of the United States Government

Not Available

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96352
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
N43CO201000095
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
STC BIOLOGICS, INC
763 D Concord Ave CAMBRIDGE, MA 02138
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Not Available
Agency: HHS
Contract: N43CO201000095
Award Amount: $299,881.00
 

Abstract:

The goal of this project is to develop STC trastuzumab, a generic version of Herceptin. Trastuzumab is a monoclonal antibody made against the HER2 protein that is overexpressed in 20-25% of patients with breast cancer. Because of very high cost associated with prescribing Herceptin, a generic version of this drug would make cancer treatment more affordable to a wider segment of the population and lower the cost burden on government-sponsored healthcare programs.  STC Biologics Inc. is uniquely positioned to address the technical challenge of reverse engineering trastuzumab as its drug development platform offers rapid and efficient analysis of post-translational modification of recombinant proteins.

Principal Investigator:

Magdalena Leszczyniecka
(617) 899-0724
mleszczyniecka@stcbiologics.com
Small Business Information at Submission:

STC BIOLOGICS, INC
182 ELM ST, UNIT 3 CAMBRIDGE, MA 02139-

EIN/Tax ID: 264335683
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No